Waycross Partners’s Amgen AMGN Stock Holding History

Waycross Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$815K	Hold	2,250	–	–	0.07%	35
2026 Q1	$792K	Hold	2,250	–	–	0.08%	37
2025 Q4	$736K	Hold	2,250	–	–	0.06%	56
2025 Q3	$635K	Hold	2,250	–	–	0.05%	63
2025 Q2	$628K	Hold	2,250	–	–	0.06%	61
2025 Q1	$701K	Hold	2,250	–	–	0.08%	50
2024 Q4	$586K	Hold	2,250	–	–	0.08%	53
2024 Q3	$725K	Hold	2,250	–	–	0.1%	55
2024 Q2	$703K	Hold	2,250	–	–	0.11%	60
2024 Q1	$640K	Hold	2,250	–	–	0.11%	61
2023 Q4	$648K	Sell	2,250 -350	-13%	-$95.4K	0.12%	68
2023 Q3	$699K	Hold	2,600	–	–	0.15%	67
2023 Q2	$577K	Hold	2,600	–	–	0.13%	77
2023 Q1	$629K	Hold	2,600	–	–	0.18%	68
2022 Q4	$683K	Hold	2,600	–	–	0.25%	63
2022 Q3	$586K	Hold	2,600	–	–	0.39%	65
2022 Q2	$633K	Hold	2,600	–	–	0.42%	63
2022 Q1	$629K	Hold	2,600	–	–	0.37%	66
2021 Q4	$585K	Hold	2,600	–	–	0.33%	71
2021 Q3	$553K	Buy	+2,600	New	+$598K	0.35%	69
2021 Q2	–	Sell	-2,600	Closed	-$647K	–	82
2021 Q1	$647K	Hold	2,600	–	–	0.36%	66
2020 Q4	$598K	Buy	+2,600	New	+$599K	0.37%	63

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Waycross Partners's AMGN Position: Q2 2026 in Review

Waycross Partners held its Amgen (AMGN) position steady in Q2 2026 at 2,250 shares worth $815K. The position accounts for 0.07% of the portfolio, ranked #35.

Waycross Partners first reported a position in AMGN in Q4 2020 and has held it in 22 quarters since. 3,149 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Waycross Partners held 2,250 shares of Amgen worth $815K as of Q2 2026.
Waycross Partners left its Amgen share count unchanged in Q2 2026.
Amgen made up 0.07% of Waycross Partners's portfolio in Q2 2026, its #35 holding.
Waycross Partners first reported a position in Amgen in Q4 2020 and has held it in 22 quarters since.
3,149 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Waycross Partners's 13F filing for Q2 2026, filed 11 Aug 2026.